COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

OCCPR Webinar: Proteomic Assay Portal

Did you know about NCI’s Proteomic (CPTAC) Assay Portal?  It’s a free resource for biological scientists performing mass spectroscopy.  The portal houses more than 2300 fit-for-purpose,...


Proteomics for the Pediatric Brain Cancer Pilot Study Released on the PDC

The Proteomic Data Commons (PDC) has released data from the Children's Brain Tumor Tissue Consortium (CBTTC): Pediatric Brain Tumor Atlas dataset!



The CBTTC and the Pacific Pediatric Neuro-Oncology Consortia (...


The CPTAC Pathology Portal Has New Images

A new batch of CPTAC histopathology imaging data has been released and is now publicly available on the TCIA CPTAC Pathology Portal.


The TCIA quarterly report lists the addition of 76 new pathology slides and 25 new pathology subjects for the cutaneous melanoma, glioblastoma multiforme, and...


GDC Releases Harmonized Genomic Data From CPTAC

Data Release-20 from the Genomic Data Commons (GDC) includes genomics from a new CPTAC project!  


The CPTAC Proteogenomic Confirmatory Study examined prospectively collected colon, breast and ovarian tumors for analysis, including harmonized whole exome sequencing, RNA-Seq, and miRNA-Seq that...


CPTAC Researchers Reveal Novel Biological Features of Kidney Clear Cell Carcinoma

Investigators with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) have generated the most comprehensive multi-omics dataset for clear cell renal cell carcinoma (ccRCC), the most commonly diagnosed kidney cancer subtype. The investigators used...


CPTAC Scientific Symposium 2019 – Great Beginnings!

Over three hundred proteomic explorers and  Clinical Proteomics Tumor Analysis Consortium (CPTAC) participants from around the country convened on the NIH Bethesda campus to share cutting-edge proteogenomic research in the first ever, public-...


One Computational Step in the Journey to Identify Biological Pathways in Cancer

Large multi-omics datasets are becoming increasingly popular for studying biological systems including the identification of biological pathways, or more broadly defined gene sets, that are associated with certain biological or clinical features of interest.


ICPC China Team Comprehensively Characterizes HBV Related Liver Cancer

Hepatocellular carcinoma (HCC), the most common form of liver cancer, occurs most often in people with hepatitis B or C viral (HBV or HCV) infections who drink large amounts of alcohol.  Unlike the recent progress of antiviral-eliminating therapy for ...


CPTAC Teams Up With UniProt!


UniProt, the leading online protein reference library, has teamed up with CPTAC!  Now, search results for your protein-of-interest will include links to the CPTAC Assay Portal for relevant peptides and assay protocols, while giving CPTAC users all the rich functional annotation in UniProt...


CPTAC Researchers Develop Novel RAS-Antibodies for the Cancer Research Community through the NCI RAS-Initiative

RAS gene mutations and their pathways have  stymied cancer researchers for decades.  RAS-driven cancers make up more than 30% of all human cancers due to their association with uncontrollable cell growth, death-signal...


Pages